Guido Lancman, MD, on Areas of Focus for Multiple Myeloma

EP: 1.Study Results Show Promise for Neoantigen Targeting Strategies Such as Peptide Vaccines

EP: 2.Recommendations for Under-Representation of African Americans in Multiple Myeloma

EP: 3.Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma

EP: 4.Genetic Patterns Could Help Doctors Identify Ultra High Risk Patients of Multiple Myeloma

EP: 5.Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma

EP: 6.Guido Lancman, MD, Discusses Promising Multiple Myeloma Treatments

EP: 7.Lisa La on Areas of Interest Within Multiple Myeloma

Now Viewing

EP: 8.Guido Lancman, MD, on Areas of Focus for Multiple Myeloma

EP: 9.Lisa La on Up-and-Coming Multiple Myeloma Research

EP: 10.Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year

In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, highlighted which multiple myeloma patient populations he believes require further research.

Transcription:

So, there are still several populations that are not receiving the same benefit from all of these new therapies. And that's patients with high-risk cytogenetics, elderly patients, frail patients, patients with renal failure, and then of course, patients who have exhausted all therapies there’s always a need to develop new therapies for those patients.